{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"16.000","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2024","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"375,457,818","primaryexch":"HKEX","ric":"2410.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BQ1N021","am":"87.62","iv":"","ew_strike":"","as":"15.570","geographic_focus":null,"incorpin":"PRC","etp_baseCur":null,"ew_amt_os":"","bd":"15.550","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-26 10:38:37.0","lo52":"13.000","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Wu Yusheng","underlying_ric":"2410.HK","hi52":"56.550","issuer_name":"TYK Medicines, Inc - B - H Shares","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"15.280","mkt_cap":"5.83","f_aum_hkd":null,"ew_sub_per_to":"","ls":"15.550","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-0.270","aum":"","issued_shares_class_B":null,"vo":"5.62","secondary_listing_flag":false,"listing_date":"20 Aug 2024","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"TYK Medicines, Inc - B - H Shares","nm_s":"TYK MEDICINES-B","sym":"2410","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"TYK Medicines Inc is a China-based company mainly engaged in developing and commercializing pharmaceutical products. The Company is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.","op":"15.600","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"8th Floor, Building T2<br/>China Eastern Binjiang Center<br/>No. 277 Longlan Road<br/>Xuhui District, Shanghai, PRC","pc":"-1.71","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"15.820","isin":"CNE100006L34","moneyness":""}},"qid":"1758890168147"}
